Cosmedicine™ IN SEPHORA STORES NOW
The Union of Beauty and Medical Science:
A Measurably Different Approach to Skin Care
NEW YORK, NY - February 21, 2006 – Klinger Advanced Aesthetics (Klinger) and Sephora announce the availability of COSMEDICINE™, a new OTC regimen-based line of topical skincare products tested for performance and safety in clinical studies designed and analyzed in consultation with Johns Hopkins Medicine, a world leader in healthcare, education, and research. The product line was formulated after extensive research that revealed unmet consumer needs in addressing healthy skin.
Klinger Advanced Aesthetics sought a skin care product formulation strategy that focused on increased skin health, that was easy to use, and whose performance and safety could be verified by a trusted third party. Johns Hopkins Medicine’s consultation on the test design and data analysis for each of the products resulted in their undergoing a rigorous level of testing uncommon in the cosmetics industry. The COSMEDICINE™ line combines OTC actives and accelerated levels of advanced ingredients that have been proven safe and effective in achieving maximum benefits. COSMEDICINE™ products are now available exclusively in all 119 Sephora stores throughout the U.S and on their website at www.sephora.com.
“We have worked to create objective standards of skin health in consultation with Johns Hopkins Medicine and to report them so that consumers can make informed decisions based on verified results about the safety and performance of products they choose to support a lifetime of healthy skin,” said Richard Rakowski, Chairman and CEO of Klinger Advanced Aesthetics. “Consumers can be confident when they choose a COSMEDICINE™ product they will be using a product that contains tested and measured ingredients that actually perform as claimed.”
___________________________________________________________________________
.
GLOBAL AESTHETIC MARKET STUDY HIGHLIGHTS NEW BUSINESS OPPORTUNITIES
The booming aesthetic procedure market is generating a wide array of new business development opportunities, according to a new research report released by Medical Insight, Inc. this week..
Light-based treatments are now mainstays of medical aesthetic practices. In 2003, nearly 20 million hair removal, skin rejuvenation, tattoo and pigmented lesion removal, acne reduction and photodynamic therapy treatments were performed. These earned almost $6.5 billion for practitioners and $372 million in revenue for equipment manufacturers. By 2008, this will grow to over 53 million treatments annually earning practitioners $10.4 billion and manufacturers more than $612 million.
Botox treatments are also popular. In 2003, four million procedures were performed worldwide, generating over $2.1 billion in procedure fees. By 2008, more than 10 million procedures will be performed annually, generating treatment revenue of $4.4 billion. Revenue to suppliers will grow from $656 million in 2003 to $1.6 billion in 2008.
Dermal filler use isn't far behind. More than two million procedures were performed in 2003, earning practitioners $1.2 billion and suppliers $196 million. In 2008, this will rise to almost five million treatments generating $2.3 billion for physicians and $398 million for suppliers.
Microdermabrasion, chemical peels and emerging skin rejuvenation treatments are also rising. In 2003, over 16 million treatments were performed, accounting for almost $3.3 billion in fees to practitioners. Equipment manufacturers and suppliers earned about $108 million. By 2008, this will grow to more than 41 million procedures earning over $6 billion for practitioners and $185 million for manufacturers.
The greatest growth and largest opportunity, however, remains anti-aging topicals. In 2003, sales of all brands through all outlets accounted for $4.1 billion. This will grow to more than $5.6 billion in 2008.
According to study author Michael Moretti, President of Medical Insight, Inc. and Editor of the Aesthetic Buyers Guide, the Global Aesthetic Market study provides the only available comprehensive market analysis and five-year forecast related to emerging and high-growth aesthetic market segments.
In addition to releasing the Global Aesthetic Market Study, Mr. Moretti has identified a priority list of current business development and investment opportunities, which is available upon request. "This Strategic Opportunities Summary is designed to give business development executives, investors and R&D managers immediate access to a select group of the most promising new concepts in this exciting, high-growth field," explained Moretti.
To obtain an Executive Summary of the Global Aesthetic Market Study, or receive the Strategic Opportunities Summary, contact Michael Moretti at: Mmoretti@MiiNews.com
Mr. Moretti has served as an industry analyst, strategic business development liaison, and editor in the high-tech medical / aesthetic field for 20 years.
Public companies participating in the aesthetic market include: Allergan (NYSE: AGN), Biolase (Nasdaq:BLTI), Candela (Nasdaq:CLZR), Cutera (Nasdaq:CUTR), Dusa (Nasdaq:DUSA), Inamed (Nasdaq:IMDC), Isolagen (AMEX: ILE), Laserscope (Nasdaq:LSCP), Lumenis (Nasdaq:LUME), Medicis (NYSE:MRX), Palomar (Nasdaq:PMTI), and PhotoMedex (Nasdaq:PHMD).\
For information on products and services offered by Medical Insight, Inc., visit www.MiiNews.com or print out our products and services order form.
Contact: Michael Moretti
Medical Insight, Inc.
(949) 830-5409
Email: Mmoretti@MiiNews.com |
